Manitol Mein (Mannitol)

Mannitol increases plasma osmolarity, drawing water from intracellular and interstitial spaces into the bloodstream. This expands plasma volume, enhances renal perfusion, and promotes the excretion of water and electrolytes, while also reducing cerebral edema by creating an osmotic gradient across the blood‑brain barrier.

The dose of Manitol is individualized by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goal. Dosage regimens are established in hospital protocols and adjusted according to clinical response and laboratory monitoring.

Safety data for mannitol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Manitol Mein, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mannitol is a non‑ionic sugar alcohol that provides rapid osmotic diuresis and intracranial pressure reduction, whereas alternatives such as hypertonic saline rely on sodium chloride to achieve similar effects. Mannitol’s renal excretion and lower sodium load make it preferable in many neurosurgical and renal‑failure scenarios, though choice depends on patient‑specific factors.

Manitol Mein should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and sterility.

Manitol is administered intravenously, typically as a sterile solution infused over a controlled period. The infusion rate and total volume are determined by the prescriber, with careful monitoring of vital signs, urine output, and serum electrolytes throughout the administration.

Serious risks include pulmonary edema, severe hypotension, anaphylactic reactions, worsening renal failure, cardiac arrhythmias, and seizures. Prompt recognition of these events and immediate medical intervention are essential to mitigate harm.

Mannitol is contraindicated in patients with severe dehydration, active intracranial bleeding, uncontrolled heart failure, severe pulmonary edema, or known hypersensitivity to mannitol. Caution is also advised in individuals with significant renal impairment or electrolyte disturbances.